Dinner Debate: How Can Networking in Science and Technology Help SMEs Meet the Innovation Union Goals?
Event Type
Organiser type
Section
Event Location
Event Description
Dinner Debate: How Can Networking in Science and Technology Help SMEs Meet the Innovation Union Goals?
Venue: European Parliament
Date: 29 January 2013 19:30-22:00
Link: http://www.cost.eu/events/k4i_dinnerdebate
On 29 January 2012 COST will organise a dinner debate together with the K4I (Knowledge 4 Innovation) Forum of the European Parliament on the topic of 'Enhancing SME cooperation in Science and Technology'. This debate aims at opening a forum where the SME voice and interest in joining European programmes is heard, promoting SMEs participation in European science and technology networking, and devising opportunities for simplified access of SMEs to participate in European research programmes.
Related Events
Securing Europe‘s Raw Material Supply in the Context of Resource Efficiency and EU Industry Policy
There is no energy- and resource efficiency, no climate protection, no future technologies for our modern
world without the use of non-ferrous metals.
Monday 5 November 2012 (day 1)
15:00-16:30: European Parliament Briefing (optional): Enterprise Forum members will have the opportunity to attend a briefing on how the European Parliament works. Paul-Henri Spaak Building, Rue Wiertz, B-1047 Brussels
SMEs are the backbone of the European economy. Of the approximately 20 million SMEs in Europe, one third is active in the field of commerce.
COST will be a partner of the fourth European Innovation Summit to be held at the European Parliament in Brussels under the motto 'Building bridges – Creating Synergies'.
Knowledge4Innovation will be organising the 4th European Innovation Summit from 9 to 10 October 2012 in the European Parliament in Brussels.
An existing literature agrees that drug innovation has a significant average effect on extending longevity and improving quality of life. Recognizing the life-saving benefits from the development of new drugs, one of the key decisions faced by the authorities is how to bolster pharmaceutical innovation, and how to bear in mind the potential effects on drug innovation of policies that affect market size, such as policies towards intellectual property rights, procurement mechanisms and competition policy.
Pages
Events of the week
Jobs
EURACTIV News
- US Treasury targets Russia’s Gazprombank with new sanctions
- Irish economy faces the test of Trump’s protectionism
- Unpopular Scholz set to run for second term after Pistorius bows out
- Romania’s radical right leader Simion, a Trump fan, eyes presidency
- Nuclear sector pins hopes on 2026 for ‘low-carbon’ hydrogen label